NCYT:LON
Novacyt SA
GBX 38,60
0,00%
(0,00) 1D
14 Okt., 16:35:03 GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NCYT...
Mkt. cap
34,29 m
Avg. vol.
101,48 k
Volume
0,00
52-wk high
GBX 86,00
52-wk low
GBX 26,60
Shares outstanding
37,66 m
No. of employees
228
Mkt. cap
34,29 m
Avg. vol.
101,48 k
Volume
0,00
52-wk high
GBX 86,00
52-wk low
GBX 26,60
Shares outstanding
37,66 m
No. of employees
228
News stories
From web sources and news partners
Chosunbiz
·
19 minute gelede
Ruling party warns Solidigm Nasdaq listing risks, urges SK hynix shareholder protection - CHOSUNBIZ
MarketBeat
·
5 minute gelede
The Honest Company, Inc. (NASDAQ:HNST) Stock Has Consensus Price Target of $4.84 According to Analysts
Benzinga
·
29 minute gelede
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA